REFERENCES
- King TE Jr , Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–1961.
- Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr , Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–643.
- Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103:1808–1812.
- Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J. 2004;11:117–122.
- Fumeaux T, Rothmeier C, Jolliet P. Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis. Intensive Care Med. 2001;27:1868– 1874.
- Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med. 2008;102:1355–1359.
- Mollica C, Paone G, Conti V, Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration. 2010;79:209–215.
- Rangappa P, Moran JL. Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis. Crit Care Resusc. 2009;11:102–109.
- Park JH, Kim DS, Park IN, Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175:705–711.
- Nishiyama O, Taniguchi H, Kondoh Y, A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010;36:1067–1072.
- Collard HR, King TE Jr , Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538–542.
- Johnson MJ, Abernethy AP, Currow DC. Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? J Pain Symptom Manage. 2012;43:614–624.
- Mahler DA, Selecky PA, Harrod CG, American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010;137:674–691.
- Marciniuk DD, Goodridge D, Hernandez P, Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18:69–78.
- Adcock JJ. Peripheral opioid receptors and the cough reflex. Respir Med. 1991;85(Suppl A):43–46.
- Portenoy RK, Sibirceva U, Smout R, Opioid use and survival at the end of life: a survey of a hospice population. J Pain Symptom Manage. 2006;32:532–540.
- Clemens KE, Klaschik E. Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage. 2007;33:473–481.
- Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med. 2008;11:204–216.
- Raghu G, Collard HR, Egan JJ, An official ATS/ERS/ JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
- Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377–381.
- Cheatle MD, Savage SR. Informed consent in opioid therapy: a potential obligation and opportunity. J Pain Symptom Manage. 2012;44:105–116.
- Bernard GR, Artigas A, Brigham KL, The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818–824.
- Lynn J. Perspectives on care at the close of life. Serving patients who may die soon and their families: the role of hospice and other services. JAMA. 2001;285:925–932.
- Ryerson CJ, Collard HR, Pantilat SZ. Management of dyspnea in interstitial lung disease. Curr Opin Support Palliat Care. 2010;4:69–75.
- Ryerson CJ, Donesky D, Pantilat SZ, Collard HR. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. J Pain Symptom Manage. 2012;43:771–782.
- Bajwah S, Ross JR, Peacock JL, Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. Thorax thoraxjnl-2012-202040 Published Online First: 1 December 2012.
- Harris-Eze AO, Sridhar G, Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD. Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med. 1995;152 (6 Pt 1):1940–1945.
- Polosa R, Simidchiev A, Walters EH. Nebulised morphine for severe interstitial lung disease. Cochrane Database Syst Rev. 2002;(3): CD002872.
- Allen S, Raut S, Woollard J, Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med. 2005;19:128–130.
- Devlin JW, Nava S, Fong JJ, Bahhady I, Hill NS. Survey of sedation practices during noninvasive positive-pressure ventilation to treat acute respiratory failure. Crit Care Med. 2007;35:2298–2302.
- Constantin JM, Schneider E, Cayot-Constantin S, Remifentanil-based sedation to treat noninvasive ventilation failure: a preliminary study. Intensive Care Med. 2007;33:82–87.
- Clouzeau B, Bui HN, Vargas F, Target-controlled infusion of propofol for sedation in patients with non-invasive ventilation failure due to low tolerance: a preliminary study. Intensive Care Med. 2010;36:1675–1680.
- Smallwood N, Peringathara B, Twigg S. Remifentanil sedation: a five year retrospective case series focusing on its role in non-invasive ventilation. J Intensive Care Soc. 2010:11;171–173.